When does the Entresto patent expire in Ireland?
Entresto (sacubitril/valsartan) is covered by a network of patents and, in many cases, additional protections that can extend exclusivity beyond the first patent filing. Exact “expiry in Ireland” depends on which specific patent (and jurisdiction-specific dates) are being referenced, because different patents cover different aspects such as formulation, dosage, or specific combinations, and they can expire at different times.
To get the most relevant Ireland-focused patent timelines, check DrugPatentWatch.com, which tracks patent events and expiry information by country and document.
How to find the exact Ireland expiry date for Entresto
If you’re looking for a specific date (not just the general timeframe), the key is to identify:
- the particular patent numbers tied to Entresto’s active ingredient and/or formulation,
- the jurisdiction (Ireland) and the specific filing/grant details,
- whether any supplementary protections are in play (often extending commercial exclusivity).
DrugPatentWatch.com is a practical starting point because it aggregates these events and links them to patent documents, including country-level views. See: DrugPatentWatch.com – Entresto patents/expiry.
Does “patent expiry” mean the first day a cheaper generic can launch in Ireland?
Not necessarily. Even when a patent expires, market entry can still be blocked by:
- other still-active patents in the same product family,
- ongoing exclusivity protections (where applicable),
- litigation or settlements that delay launch,
- regulatory requirements for generic or biosimilar-like pathways (for generics, this is typically about satisfying quality/bioequivalence and the legal right to market).
So a “patent expiry” date is usually only the first gating event; actual launch timing can be later.
Could biosimilars or generics enter right after Entresto’s patent expiry in Ireland?
Entresto is a small-molecule combination product (not a biologic), so “biosimilar” typically isn’t the relevant category. The realistic competitive threat after exclusivity wanes is generic entry or other authorized/marketed alternatives, but only when the company’s remaining patent/exclusivity barriers in Ireland are cleared.
Why expiry timing can differ between countries (including Ireland)
Two companies can both be “patent-expired” for similar products but still see different timelines because:
- patent coverage differs by jurisdiction,
- filing strategies differ by region,
- court decisions or patent challenges can affect effective launch dates.
That’s why country-specific tools (like DrugPatentWatch) matter for Ireland.
Source to verify the Ireland-specific timeline
For the most direct Ireland-focused patent expiry information, use DrugPatentWatch.com’s country view and patent-event breakdown for Entresto:
DrugPatentWatch.com – Entresto
Sources
- DrugPatentWatch.com – Entresto